Abstract By direct sequencing of regions of the human genome containing five genes belonging to the acetyltransferase family, arylamine N-acetyltransferase (NAT1), arylamine N-acetyltransferase (NAT2), arylalkylamine Nacetyltransferase (AANAT), L1 cell adhesion molecule (L1CAM), and the human homolog of Saccharomyces cerevisiae N-acetyltransferase ARD1, we identified 53 single-nucleotide polymorphisms (SNPs) and two insertion/ deletion polymorphisms in 48 healthy Japanese volunteers. NAT1 and NAT2 are so-called drug-metabolizing enzymes. In the NAT1 gene we found two SNPs and a 3-bp insertion/ deletion polymorphism that corresponded to the NAT1*3,
Introduction
N-acetyltransferase (NAT), first identified as an inactivator of the anti-tubercular drug isoniazid (Hughes et al. 1954) , refers to two structurally related isoenzymes called NAT1 and NAT2 (Blum et al. 1990 ). NAT1 specifically catalyzes acetylation for arylamine acceptor structures, such as p-aminosalicylic acid and p-aminobenzoic acid (Minchin 1995; Sim and Ward 1995) . NAT2 acetylates other arylamine-acceptor structures, such as isoniazid, caffeine, procainamide, and sulfasalazine (Grant et al. 1983; Hughes et al. 1954; Reidenberg 1984; Sabbagh et al. 1997) . Specific types of NAT1 and NAT2 alleles have been correlated with distinct metabolic activities, and also with the presence or absence of side effects for these drugs Lin et al. 1998; Grant et al. 1997 Grant et al. , 2000 Hein et al. 1994 Hein et al. , 2000 Leff et al. 1999) .
Another enzyme, arylalkylamine N-acetyltransferase (AANAT), converts serotonin, as well as synthetic arylethylamine derivatives, to N-acetyl forms by transferring an acetyl group from acetyl coenzyme A. AA-NAT may play a major role in the regulation of melatoninassociated circadian rhythm in vertebrates (Delagrange and Guardiola-Lemaitre, 1997 ).
The L1 cell adhesion molecule (L1CAM) shows 40% identity of amino-acid sequence with the Nacetyltransferase that is a human homolog of Saccharomyces cerevisiae ARD1 (Tribioli et al. 1994) . N-terminal acetyltransferases, such as ARD1 and L1CAM, transfer acetyl groups from acetyl-CoA to the termini of α-amino groups during the proteolytic processing of completely translated protein and peptide hormones (Polevoda et al. 1999) .
Genetic variations can alter the expression levels and/or biological function(s) of a gene product. Hence, genetic variations in genes encoding drug-metabolizing enzymes may be associated with differences in therapeutic efficacy and side effects among individual patients. We have been focusing on identifying polymorphisms in genomic regions that encode drug-metabolizing enzymes; such sites should be useful markers for studying the correlation of genotype with phenotype, as regards the activity of Nacetyltransferases. We report here the discovery of numerous novel polymorphisms in genomic DNAs encoding NAT1, NAT2, AANAT, ARD1, and L1CAM.
Materials and methods

Amplification of samples
Total genomic DNAs were isolated by phenol/chloroform extraction from peripheral leukocytes of 48 healthy Japanese volunteers who provided their informed consent. We screened all 96 chromosomes for SNPs after designing polymerase-chain-reaction (PCR) primers to amplify known Nacetyltranferase genes, including about 1 kb upstream of the predicted first exon in genes where the complete genomic DNA sequence was unknown. We eliminated genomic regions containing repetitive DNA sequences using the Repeat Masker computer program . Each amplification reaction was performed with 60 ng of mixed genomic DNA derived from three individuals. Total reaction volumes of 20µl contained dNTPs (25mM each), MgCl 2 , 10 ϫ PCR buffer (2µl), dimethylsulfoxide (2 µl or zero, depending on PCR efficiency), PCR primers (20 pmol each), and Ex-Taq polymerase (2.5 U; Takara Tokyo, Japan). All 16 mixed samples were amplified in the GeneAmp PCR system 9700 (PE Applied Biosystems, Foster City, CA, USA) under the following conditions: initial denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 55 or 60°C for 2 min, and extension at 72°C for 30 s.
Detection of SNPs and insertion/deletion polymorphisms
Fluorescent dye-terminator cycle sequencing (ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit; PE Applied Biosystems) was performed using four primers for each amplified fragment (two for the forward side and two for the reverse side). Dye-terminated PCR amplifications were analyzed with an ABI 3700 autosequencer (PE Applied Biosystems). Detection of polymorphism was carried out using the PolyPhred computer program (Nickerson et al. 1997) , which automatically detects the presence of heterozygous SNPs by fluorescence-based sequencing of PCR products Seki et al. 2000; Yamada et al. 2000; Iida et al. 2001) . Allele frequencies were estimated individually by comparing the peak levels of signals among all 192 chromosomes.
Results and discussion
The human NAT1 and NAT2 genes are located on chromosome 8p22 (Blum et al. 1990) , and share 81% nucleotidesequence identity within their coding regions. However, the NAT1 gene has a single exon, while NAT2 consists of two 
Exon 2 exons, one corresponding to the coding region and 3Ј untranslated sequence, and the other corresponding to the 5Ј untranslated region about 8 kb upstream of the second exon. We identified 53 SNPs and two insertion/deletion polymorphisms by direct sequencing of DNA from 96 Japanese chromosomes. In the NAT1 gene, which covers a 1.6-kb genomic region, two SNPs and a 3-bp insertion/deletion polymorphism were present in the 3Ј untranslated region (Fig. 1A, Table 1 ). However, these polymorphisms were not novel; they were identical to variants reported elsewhere as NAT1*3, NAT1*10, NAT1*18A, and NAT1*18B alleles. Although 22 additional allelic variants of NAT1 were identified previously (www.louisville.edu/ medschool/pharmacology/NAT.html), we found only these 3 among our Japanese subjects. The frequencies of NAT1* alleles reported in Caucasians were 3% for NAT1*3, 16% for NAT1*10, 4.5% for NAT1*11, and 77% for NAT1*4 (rapid acetylator), as opposed to frequencies of 1.0% for NAT1*3, 40.6% for NAT1*10, 2.6% for NAT1*18A, 3.1% for NAT1*18B, and 52.6% for NAT1*4 in the Japanese population (Table 2) . Although a large part of both ethnic groups consisted of NAT1*4 and NAT1*10, in terms of allele frequency, their frequencies are quite different. Furthermore, NAT1*11 was not identified in Japanese. In addi- Fig. 1A . NAT1*15 (Arg187stop) and NAT1*19 (Arg33stop) proteins are truncated at about 90 and 240 amino acids from the carboxyl terminus, and NAT1*17 (Arg64Trp) and NAT1*22 (Asp251Val) proteins result in significant functional impairment of NAT1 (Lin et al. 1998 ). The dichotomy between these reports and our results implies a difference between Japanese and Caucasian populations with regard to genotypes at the NAT1 locus. Within the NAT2 gene, which encompasses a 17-kb genomic region, 32 SNPs and a 1-bp insertion/deletion polymorphism were identified (Fig. 1B) ; 6 SNPs were in the coding region, 8 were present in the 5Ј flanking region, and 18 in the 3Ј flanking region; the insertion/deletion polymorphism was in the 3Ј flanking region. Four of the 6 SNPs in the coding region would cause amino-acid substitutions (Ile114Thr, Arg197Gln, Lys268Arg, and Gly286Glu); these six sites corresponded to alleles already designated NAT2*5B, *6A, *6B, *7A, *7B, and 12A. Two of the 8 SNPs in the 5Ј flanking were reported in the dbSNP of GenBank. The remaining 24 SNPs and the insertion/deletion polymorphism we found in flanking regions were novel.
Genetic variations in NAT2 have been shown to correlate with metabolic activities. A total of 13 SNP sites in the coding region have been reported to date, and nucleotide substitutions in each allele have been observed at a single site or at multiple sites. So far, 27 different polymorphic Fig. 2A-C Intron 24 221 C/T a For SNPs, positions within introns are counted from the first intronic nucleotide at the exon/intron junction. Within the 5Ј flanking region, nucleotide positions are counted from the 3Ј end of the 5Ј sequence; i.e., the 3Ј-most nucleotide of the 5Ј flanking region is number Ϫ1. Within the 3Ј untranslated region (UTR), nucleotide position is counted from the first exonic nucleotide in the 3Ј untranslated region. Within the exon, nucleotide position is counted from the first exonic nucleotide b SNPs previously reported in the dbSNP of GenBank sites have been reported (www.louisville.edu/medschool/ pharmacology/NAT.html); among them, four clusters consisting of 19 alleles (NAT2*5, NAT2*6, NAT2*7, and NAT2*14) appear to confer slow acetylation. Amino-acid substitutions in NAT2*5 reduce the rate of substrate turnover, whereas in NAT2*6, NAT2*7, and NAT2*14 they reduce protein stability. Ethnic differences in allelic distribution have also been reported. In Caucasians, 17 allelic variants of the NAT2 gene have been identified; in that population the rapid acetylator NAT2*4 is present at a lower frequency (21.6%) than slow acetylators (NAT2*5B, 41.6%; NAT2*6A, 23.6%; others, 5.5%) (Agundez et al. 1996) . On the other hand, in the Japanese population, the rapid-type NAT2*4 was present at a higher frequency (51.3%) than the slow-type (NAT2*5B, 1.6%, NAT2*6A, 26.1%, NAT2*6B, 2.2%, NAT2*7A, 1.2%, NAT2*7B, 10.1%) ( Table 2 ). These frequencies were similar to those reported by Okumura et al. (1997) (NAT2*4, 68.6%, NAT2*6A, 19.3%, NAT2*7B, 9.7%, NAT2*5B, 2.4%). We also identified rare NAT2 variants, NAT2*6B and NAT2*7A, which had not been reported before in the Japanese population. The human AANAT gene is located on chromosome 7q25 (Coon et al. 1996) , and the ARD1 and L1CAM genes are at Xq28 (Tribioli et al. 1994) . Within the AANAT gene's 3.5-kb genomic region we discovered four SNPs, two in the 5Ј flanking region, one in exon 4, and one in intron 3 ( Fig.  2A, Table 3 ). In the 6.2-kb ARD1 gene, nine SNPs were identified, all of them in introns (Fig. 2B, Table 3 ). In the 16-kb L1CAM gene, we found six intronic SNPs (Fig. 2C , Table 3 ). The genetic basis for variations among Nacetyltransferase genes may be associated with differences among individuals as regards the therapeutic efficacy and safety of drugs, and hormonal regulation.
